Experts say New Jersey faces a growing challenge: While it’s still a major draw for pharmaceutical research and development, speed to market has become increasingly important to life sciences users. That means the state’s lack of move-in-ready lab space — and its lengthy approval process for new construction — puts it at a disadvantage to competing markets.
After decades of consolidation by Big Pharma, demand for modern lab and diagnostic space in New Jersey is on the rise, fueling rent growth and pushing some developers to consider new laboratory projects.
A growing pipeline of young life sciences firms has offered a second chance for New Jersey’s stock of legacy laboratory space. In the process, the ventures have served as anchors for developers seeking to repopulate large, vacant pharmaceutical campuses with turnkey laboratories.